Figure 3
From: The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms
DRV treatment reduced albuminuria in HIV-transgenic mice. HIV-transgenic mice (Tg26) were treated daily for 35 days with vehicle control, AZT, DRV, or DRV + AZT. ACR did not change in mice given vehicle control (p = 0.489) or AZT (p = 0.37), but decreased in DRV (p < 0.01) and DRV + AZT groups (p = 0.04) (A). There was no difference in BUN between groups at baseline or after 5 weeks of treatment (B).
